Transgenic expression of dominant-active IDOL in liver causes diet-induced hypercholesterolemia and atherosclerosis in Mice

Circulation Research

Volumn 115, Issue 4, 2014, Pages 442-449

  Calkin, Anna C ^a,b,c   Lee, Stephen D ^a,b   Kim, Jason ^a   Van Stijn, Caroline M W ^a   Wu, Xiao Hui ^a   Lusis, Aldons J ^a   Hong, Cynthia ^a,b   Tangirala, Rajendra I ^a   Tontonoz, Peter ^a,b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

atherosclerosis; cholesterol; LDL; ubiquitin protein ligases

Indexed keywords

APOLIPOPROTEIN E3; CHOLESTEROL; CHOLIC ACID; LIPID; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROTEIN IDOL; RECEPTOR PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; ALBUMINOID; AUTACOID; MYLIP PROTEIN, HUMAN; ORPHAN NUCLEAR RECEPTOR; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIETARY INTAKE; EXPERIMENTAL ATHEROSCLEROSIS; FEMALE; HYPERCHOLESTEROLEMIA; INFLAMMATION; LIPID BLOOD LEVEL; LIVER; LYSOSOME; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR GENE; TRANSGENIC MOUSE; ANIMAL; AORTA DISEASE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD; C57BL MOUSE; DISEASE MODEL; ENZYMOLOGY; GENETICS; HUMAN; LIPID DIET; METABOLISM; MUTATION; PATHOLOGY; TIME FACTOR; WESTERN DIET;

ALBUMINS; ANIMALS; AORTA; AORTIC DISEASES; APOLIPOPROTEIN E3; ATHEROSCLEROSIS; CHOLESTEROL, LDL; DIET, HIGH-FAT; DIET, WESTERN; DISEASE MODELS, ANIMAL; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION MEDIATORS; LIVER; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; ORPHAN NUCLEAR RECEPTORS; PLAQUE, ATHEROSCLEROTIC; PROMOTER REGIONS, GENETIC; RECEPTORS, LDL; TIME FACTORS; UBIQUITIN-PROTEIN LIGASES;

EID: 84905185274     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.304440     Document Type: Article

References (16)

1. Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science. 2009;325:100-104.
2. Calkin AC, Goult BT, Zhang L, Fairall L, Hong C, Schwabe JW, Tontonoz P. FERM-dependent E3 ligase recognition is a conserved mechanism for targeted degradation of lipoprotein receptors. Proc Natl Acad Sci U S A. 2011;108:20107-20112.
3. Scotti E, Hong C, Yoshinaga Y, Tu Y, Hu Y, Zelcer N, Boyadjian R, de Jong PJ, Young SG, Fong LG, Tontonoz P. Targeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists. Mol Cell Biol. 2011;31:1885-1893.
4. Chasman DI, Paré G, Mora S, Hopewell JC, Peloso G, Clarke R, Cupples LA, Hamsten A, Kathiresan S, Mälarstig A, Ordovas JM, Ripatti S, Parker AN, Miletich JP, Ridker PM. Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet. 2009;5:e1000730.
5. Weissglas-Volkov D, Calkin AC, Tusie-Luna T, Sinsheimer JS, Zelcer N, Riba L, Tino AM, Ordoñez-Sánchez ML, Cruz-Bautista I, Aguilar-Salinas CA, Tontonoz P, Pajukanta P. The N342S MYLIP polymorphism is associated with high total cholesterol and increased LDL receptor degradation in humans. J Clin Invest. 2011;121:3062-3071.
6. Sorrentino V, Fouchier SW, Motazacker MM, Nelson JK, Defesche JC, Dallinga-Thie GM, Kastelein JJ, Kees Hovingh G, Zelcer N. Identification of a loss-of-function inducible degrader of the low-density lipoprotein receptor variant in individuals with low circulating low-density lipoprotein. Eur Heart J. 2013;34:1292-1297.
7. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34-47.
8. van Vlijmen BJ, van 't Hof HB, Mol MJ, van der Boom H, van der Zee A, Frants RR, Hofker MH, Havekes LM. Modulation of very low density lipoprotein production and clearance contributes to age- and gender- dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice. J Clin Invest. 1996;97:1184-1192.
9. Paigen B, Morrow A, Brandon C, Mitchell D, Holmes P. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis. 1985;57:65-73.
10. Le May C, Berger JM, Lespine A, Pillot B, Prieur X, Letessier E, Hussain MM, Collet X, Cariou B, Costet P. Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1. Arterioscler Thromb Vasc Biol. 2013;33:1484-1493.
11. Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest. 1994;93:1885-1893.
12. Purcell-Huynh DA, Farese RV Jr, Johnson DF, Flynn LM, Pierotti V, Newland DL, Linton MF, Sanan DA, Young SG. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J Clin Invest. 1995;95:2246-2257.
13. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258:468-471.
14. Westerterp M, van der Hoogt CC, de Haan W, Offerman EH, Dallinga- Thie GM, Jukema JW, Havekes LM, Rensen PC. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler Thromb Vasc Biol. 2006;26:2552-2559.
15. Zadelaar S, Kleemann R, Verschuren L, de Vries-Van der Weij J, van der Hoorn J, Princen HM, Kooistra T. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol. 2007;27:1706-1721.
16. den Boer MA, Westerterp M, de Vries-van der Weij J, Wang Y, Hu L, Espirito Santo SM, Kooistra T, Reiss P, Romijn JA, Havekes LM, Rensen PC. Ritonavir protects against the development of atherosclerosis in APOE*3-Leiden mice. Atherosclerosis. 2010;210:381-387.